Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 16/20 | 0.47 |
| ▸ | GSK3B | P49841 | 15/20 | 0.47 |
| ▸ | WNT1 | P04628 | 13/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25611175 | 0.84 | GSK3B (0.57) | DYRK1AGSK3BWNT1JAK2TYK2 | |
| SCHEMBL25611177 | 0.84 | DYRK1A (0.46) | DYRK1AGSK3BWNT1ABL1 | |
| SCHEMBL25608970 | 0.83 | DYRK1A (0.49) | DYRK1AGSK3BWNT1JAK2TYK2 | |
| SCHEMBL31272093 | 0.83 | DYRK1A (0.49) | DYRK1AGSK3BWNT1JAK2TYK2 | |
| SCHEMBL31271929 | 0.82 | GSK3B (0.54) | DYRK1AGSK3BWNT1JAK2TYK2 | |
| SCHEMBL25609003 | 0.82 | GSK3B (0.54) | DYRK1AGSK3BWNT1JAK2TYK2 | |
| SCHEMBL25614115 | 0.81 | GSK3B (0.54) | DYRK1AGSK3BWNT1JAK2TYK2 | |
| SCHEMBL25613020 | 0.80 | GSK3B (0.55) | DYRK1AGSK3BWNT1JAK2TYK2 | |
| SCHEMBL25611226 | 0.80 | GSK3B (0.52) | DYRK1AGSK3BWNT1JAK2TYK2 | |
| SCHEMBL25611374 | 0.80 | DYRK1A (0.46) | DYRK1AGSK3BWNT1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |